November 19, 2025 – TheNewswire - Vancouver, British Columbia, Canada -  Neurothera Labs Inc. (TSXV: NTLX) (“Neurothera” or the “Company”), a clinical-stage biotech company and an wholly-own subsidiary of SciSparc Ltd. (Nasdaq: SPRC), today announced that Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) has filed an Israeli patent application for an innovative combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, such as Palmitoylethanolamide (PEA), addressing depression.The pate ...